EFG Asset Management North America Corp. Has $1.85 Million Holdings in IQVIA Holdings Inc. $IQV

Key Points

• EFG Asset Management North America Corp. has reduced its stake in IQVIA Holdings Inc. by 23.8%, bringing its holdings to 10,468 shares valued at approximately $1.85 million.
• Wall Street analysts have raised their price targets for IQVIA, with estimates now ranging from $180 to $235, leading to a consensus rating of "Moderate Buy".
• IQVIA reported a quarterly earnings per share of $2.81, exceeding analyst expectations, and plans to achieve an FY 2025 EPS guidance between $11.750 and $12.050.

EFG Asset Management North America Corp. cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 23.8% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 10,468 shares of the medical research company's stock after selling 3,268 shares during the period. EFG Asset Management North America Corp.'s holdings in IQVIA were worth $1,845,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC increased its stake in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after buying an additional 2,537 shares during the period. Aptus Capital Advisors LLC acquired a new stake in shares of IQVIA during the fourth quarter valued at about $284,000. Bank of America Corp DE lifted its stake in shares of IQVIA by 30.3% in the fourth quarter. Bank of America Corp DE now owns 1,255,535 shares of the medical research company's stock worth $246,725,000 after acquiring an additional 291,816 shares in the last quarter. Baird Financial Group Inc. grew its stake in IQVIA by 2.2% during the 4th quarter. Baird Financial Group Inc. now owns 61,023 shares of the medical research company's stock valued at $11,992,000 after purchasing an additional 1,319 shares in the last quarter. Finally, Cary Street Partners Financial LLC purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $1,422,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

IQV has been the topic of a number of research analyst reports. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Evercore ISI increased their price target on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. JPMorgan Chase & Co. lowered their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Robert W. Baird increased their target price on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 target price on shares of IQVIA in a research note on Wednesday, September 3rd. Eighteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average price target of $229.64.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Performance

Shares of NYSE:IQV traded up $2.21 during trading hours on Tuesday, hitting $189.89. The stock had a trading volume of 1,196,574 shares, compared to its average volume of 1,916,591. The stock's fifty day simple moving average is $180.48 and its 200 day simple moving average is $167.20. The firm has a market capitalization of $32.28 billion, a price-to-earnings ratio of 27.48, a PEG ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.